Takeda's Zasocitinib Demonstrates Superior Efficacy in Phase 3 Psoriasis Trials

Takeda has announced new data from three Phase 3 LATITUDE psoriasis studies for zasocitinib (TAK-279), an investigational oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis. Presented at the European Academy of Dermatology & Venereology (EADV) Congress 2026, the results showed zasocitinib's superior efficacy compared to deucravacitinib, with higher rates of complete skin clearance observed as early as week 8 and durable, consistent improvements.